Originally dba as Innotech LLC., InnoTech Precision Medicine is collaborating with MIT to develop a multiplexed biosensor platform for SARs-Cov-2 Testing and other medical conditions. The created team is leveraging the strengths of antigen and nucleic acid testing by multiplexing up to eight biosensors for selective detection of their corresponding protein and nucleic acid targets. The overall defined mission of the firm is the development of a platform for rapid, accurate, low-cost, field-deployable, and early point-of-care/self-test diagnosis of diseases from the easily accessible liquid biopsy.
